Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni,1,4 Sumeet A. Khetarpal,1,6 Daniel B. Larach,1,7 William F. Hancock-Cerutti,1,2 John S. Millar,1 Marina Cuchel,1

that additional human genetic analyses might causally protective against CHD, we reasoned suggest that higher HDL-C levels may not be by ~5 mg/dl, was found to have no association lower risk of coronary heart disease (CHD). Mice that have depleted cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL). CARDIoGRAM Exome Consortium, Global Lipids Genetics Consortium unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased risk of coronary heart disease (CHD) (odds ratio = 1.79, which is statistically significant). Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have derived from induced pluripotent stem cells from the homozygous subject, and in mice. Scavenger receptor class BI (SR-BI), encoded on atherosclerosis opposite to those predicted by human epidemiological data: Overexpression reduces atherosclerosis despite the lower HDL-C levels. SR-BI knockout reduces macrophage RCT, and SR-BI overexpression increases macropage RCT, and SR-BI knockout reduces macrophage RCT (2f). The human relevance of these observations has been unclear.

Identification of SCARB1 P376L homozygote and association with extremely high HDL-C

We hypothesized that humans with extremely high levels of HDL-C may harbor loss-of-function variants in SCARB1 and undertook a targeted re-sequencing discovery experiment in 328 participants with very high HDL-C (>95th percentile, mean HDL-C of 106.8 mg/dl) and a control group of 388 subjects with low HDL-C (<25th percentile, mean HDL-C of 30.4 mg/dl). In this cohort, we sequenced the exons of ~990 genes located within 300 kb of each of the 95 loci with significant associations (P < 5 × 10−8) with plasma lipid levels identified by the Global Lipids Genetics Consortium as of 2010 (22). Among the high HDL-C subjects, we identified a homozygote for SCARB1 P376L (rs125384671 G>A, c.1127 C>T, p.P376L, rs74830677), a 67-year-old female with an HDL-C of 152 mg/dl, and confirmed this finding by Sanger sequencing. This subject harbored no mutations in other high HDL-C genes such as CETP and LIPC. In addition to this homozygote, four P376L heterozygotes were identified by targeted sequencing in the high HDL-C group; no heterozygotes were found in the low HDL-C group (P = 0.008, Fisher's exact test).

To identify additional P376L carriers, we genotyped an expanded cohort of very high versus low HDL-C subjects. Among 524 additional subjects with very high HDL-C (mean HDL-C 95.0 mg/dl), we identified 11 heterozygotes for P376L; whereas among 758 subjects with low HDL-C (mean HDL-C 33.5 mg/dl), we identified 3 heterozygotes. In total, our combined sequencing and genotyping for discovery of the P376L variant showed that this variant is significantly overrepresented in subjects with high HDL-C (minor allele frequency (MAF) = 0.010 in high HDL-C versus 0.0013 in low HDL-C controls, P = 6.000127, Fisher's exact test, Table 1).

Because this variant is present on the exome array, we expanded our analysis to the Global Lipid Genetics Consortium exome array data in >300,000 individuals. The P376L variant was very rare in this population (MAF of ~0.0003). It was significantly associated with higher HDL-C levels with a relatively large effect size (beta = 8.4 mg/dl; P = 1.4 × 10−25). Notably, this variant was not associated with plasma levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides (TGs) (table S1). Thus, we conclude that SCARB1 P376L is associated specifically with elevated HDL-C levels.

HDL-related phenotypes of SCARB1 P376L homozygote and heterozygotes

We next recruited the P376L homozygote, eight heterozygous carriers, and both high HDL-C and normal HDL-C noncarrier controls for deep phenotyping of HDL metabolism and related traits. All of the P376L study participants were of...
European ancestry, almost exclusively of Ashkenazi Jewish descent. Clinical characteristics and lipid profiles of the subjects are reported in Table 2.

Fast protein liquid chromatography (FPLC) analysis of plasma lipoproteins confirmed the increase in large HDL particles in the homozygote (Fig. 1A). Cholesterol and apolipoprotein A-I (apoA-I) levels in HDL were significantly increased in the homozygote and heterozygotes compared with controls, but HDL apoA-II levels were not elevated (Table 2 and Fig. 1B). There were no differences between P376L carriers and controls in the absolute amount of HDL free cholesterol or the ratio of free-to-esterified cholesterol in their HDL (Fig. 1C). P376L heterozygotes had a 2.8-fold increase and the homozygote a 6.1-fold increase in large HDL-2b particles compared with noncarrier controls (Fig. 1D). There was more apoA-I (Fig. 1E and fig. S2) and apoC-III (Fig. 1F) in large HDL particles in the homozygote and heterozygous carriers. Cholesterol efflux capacity was similar in carriers and controls (Fig. 1G). In contrast to the infertility phenotype of Scarb1-deficient female mice (18), the P376L homozygote had two healthy children and reported no fertility impairment. We also did not observe the steroidogenic or platelet phenotypes reported in Scarb1-deficient mice (see supplementary materials).

**SCARB1 P376L results in complete loss of function of SR-BI**

Given the profound HDL-phenotype of the P376L carriers, we wanted to understand the impact of the variant on SR-BI function. We generated induced pluripotent stem cells (iPSCs) using peripheral blood mononuclear cells from the P376L carriers and a noncarrier control. We next differentiated these cells into hepatocyte-like cells (HLCs) to study HDL metabolism in the setting of endogenous cellular SCARB1 expression. HLCs differentiated through this protocol recapitulate phenotypes of cultured primary hepatocytes such as albumin and VLDL (very low density lipoprotein) secretion (23–26). The cell lines from the control donor and the P376L homozygous subject demonstrated expression of hepatocyte-specific genes ALB (albumin) and AFP (alpha-fetoprotein) and exhibited comparable SCARB1 gene expression (fig. S3). Compared with control iPSC hepatocyte lines, those from the P376L homozygote demonstrated a profound reduction in selective cholesterol uptake from HDL in vitro (Fig. 2A). Similar results were observed in experiments with COS7 cells transfected with plasmids expressing wild-type (WT) or the P376L variant of SCARB1 (fig. S3, A and B), along with definitive binding to HDL in vitro at 4°C (fig. S4, C and D).

To evaluate the physiological impact of the P376L variant on HDL-C levels and catabolism in vivo, we used adeno-associated virus (AAV) vectors to direct hepatic overexpression of WT SR-BI or the P376L variant in mice with depleted Scarb1 (Scarb1 knockout [KO] mice). The two groups of mice demonstrated similar hepatic expression levels of Scarb1 mRNA (fig. S3A) and SR-BI protein (fig. S3B). Mice expressing WT Scarb1 demonstrated a robust 70% decrease in HDL-C. In contrast, mice expressing the P376L variant had no reduction in HDL-C; their HDL-C levels were comparable to those in the control AAV-null injected mice (Fig. 2B). Although the clearance of 125I-labeled protein was not different among the three groups, the clearance of 125I-HDL-C was much slower in mice expressing the P376L variant compared with those expressing WT SR-BI and was comparable to that in the control mice (Fig. 2, C and D). Selective HDL-C clearance from plasma was increased by WT SR-BI but was undetectable in the P376L-expressing mice (Fig. 2E and fig. S3C), as was hepatic uptake of 125I-HDL-C at 24 hours (fig. S5D). This indicates that the P376L sequence variant results in complete loss of the canonical function of SR-BI—namely, selective uptake of HDL-C.

We hypothesized that the markedly reduced HDL-C uptake could be because of aberrant processing of the P376L SR-BI protein, which leads to impaired cell surface localization. To test this, we isolated cell surface proteins from COS7 cells transfected with WT and P376L SR-BI using bidimensional gel electrophoresis and found markedly reduced cell surface SR-BI in the P376L transfected cell lysates after streptavidin cell surface protein pulldown assays (fig. S4E). Given that SR-BI undergoes N-glycosylation in the endoplasmic reticulum concomitant with proper folding, we hypothesized that altered posttranslational modification may underlie its reduced cell surface localization (27–29). We measured the molecular weights of SR-BI forms after endoglycosidase-H (Endo-H) treatment of transfected COS7 (fig. S4E) and iPSC-derived HLC.

| Table 1. Association of SCARB1 P376L with HDL-C in high versus low HDL-C cohorts. Carriers of the P376L variant were ascertained from the Penn High HDL Study through two approaches, targeted sequencing of the SCARB1 gene in a total of 726 subjects (328 high HDL-C and 398 low HDL-C subjects) and genotyping on the exome array (Illuma) in an additional 1282 subjects (524 high HDL-C subjects and 758 low HDL-C subjects). The association of the P376L variant with the high HDL-C cohort from both approaches individually and combined together was tested using Fisher’s exact test. N, number of participants; NonC, noncarriers; Het, heterozygotes; Hom, homozygotes. |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Discovery cohort | High HDL-C (≥95th percentile) (N) | Low HDL-C (≤25th percentile) (N) | Association (P) |
| Targeted sequencing of SCARB1 | 328 | 323 | 4 | 1 | 398 | 398 | 0 | 0.008398 |
| Exome array genotyping | 524 | 513 | 11 | 0 | 758 | 755 | 3 | 0.005296 |
| Combined | 852 | 836 | 15 | 1 | 1156 | 1153 | 3 | 0.000127 |
|  |  |  |  |  |  |  |  |  |
lysates, as well as mouse liver lysates expressing WT or mutant SR-BI (Fig. 2, F and G). Higher-molecular-weight forms represent N-glycosylation modified Endo-H–resistant and partially sensitive forms at the cell surface after modification by alpha-mannosidase II in the Golgi apparatus (28).

In the iPSC-derived differentiated HCLs from the P376L homozygote (Fig. 2F), we found much less total cellular SR-BI in the mutant cell lines relative to that of WT cells, despite comparable SCARB1 gene expression (fig. S3C). After Endo-H treatment, the SR-BI from SCARB1 WT cell and liver lysates across models was predominantly the partially sensitive form, along with small amounts of the fully resistant form. In contrast, the SR-BI from cell and tissue lysates across P376L-expressing groups was all the immature, fully Endo-H–sensitive form (Fig. 2, F and G, and fig. S4F). Together, these data

![Fig. 1. HDL composition and functionality in a SCARB1 P376L homozygote, heterozygous carriers, and controls.](image)

**Table 2. Characteristics of SCARB1 P376L carriers and controls recruited for deep phenotyping.** Demographic, plasma lipid, and apolipoprotein traits measured from one P376L homozygote, eight heterozygotes, and noncarrier controls from subjects identified from sequencing or genotyping of the Penn High HDL Study cohort for deep phenotyping. Lipid measurements from plasma were performed using an autoanalyzer. Where applicable, data are presented as means ± SD. Numbers correspond to groups for comparison. Group 1, normal HDL-C controls; group 2, high HDL-C controls; group 3, SCARB1 P376L heterozygotes. Tested: ANOVA or chi-square. Groups: Comparison between groups by number with Tukey’s multiple comparison. *Significant at $P < 0.05$. **Significant at $P < 0.05$ by chi-square but not ANOVA. Dash indicates no significant comparison. BMI, body mass index; PTA, phosphotungstate precipitation method; VLDL, very low density lipoprotein; Lp(a), lipoprotein a.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Group</th>
<th>Significance</th>
<th>Tested</th>
<th>Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>P376L Hom</td>
</tr>
<tr>
<td>Number of subjects</td>
<td>11</td>
<td>10</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.6 (9.7)</td>
<td>64.2 (12.5)</td>
<td>67.5 (15.3)</td>
<td>65</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>6/5</td>
<td>5/5</td>
<td>6/2</td>
<td>0/1</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.4 (2)</td>
<td>22.9 (1.3)</td>
<td>25.6 (3.9)</td>
<td>21</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>185.8 (22.3)</td>
<td>215.8 (29.9)</td>
<td>228 (33.2)</td>
<td>280</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>93.5 (2.9)</td>
<td>91.6 (7.0)</td>
<td>98.8 (5.3)</td>
<td>86</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>1091 (17.3)</td>
<td>974 (21.6)</td>
<td>116.6 (27.1)</td>
<td>109</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>51 (11.4)</td>
<td>110.1 (19.8)</td>
<td>86.9 (19.9)</td>
<td>152</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>121.2 (35)</td>
<td>71.5 (32.3)</td>
<td>99.5 (23.7)</td>
<td>57</td>
</tr>
<tr>
<td>Alcohol &gt;1/day (g)</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>VLDL-C (mg/dl)</td>
<td>26.9 (8.8)</td>
<td>19 (6.2)</td>
<td>23.1 (9.2)</td>
<td>13</td>
</tr>
<tr>
<td>Lp(a) (mg/dl)</td>
<td>22.3 (18.8)</td>
<td>19 (22.7)</td>
<td>15.9 (21.2)</td>
<td>17</td>
</tr>
<tr>
<td>apoA-I (mg/dl)</td>
<td>172.2 (33.3)</td>
<td>241.7 (41.2)</td>
<td>229.6 (36.1)</td>
<td>327</td>
</tr>
<tr>
<td>apoA-II (mg/dl)</td>
<td>40.5 (7)</td>
<td>49.5 (11.5)</td>
<td>46.6 (5.5)</td>
<td>45</td>
</tr>
<tr>
<td>apoB (mg/dl)</td>
<td>99.7 (13.4)</td>
<td>82.8 (17.1)</td>
<td>95.9 (18.2)</td>
<td>92</td>
</tr>
<tr>
<td>apoC-III (mg/dl)</td>
<td>4.32 (1.55)</td>
<td>6.09 (2.69)</td>
<td>4.49 (2.17)</td>
<td>5.3</td>
</tr>
<tr>
<td>apoC-III (mg/dl)</td>
<td>11.4 (4.3)</td>
<td>15.5 (6.9)</td>
<td>13.7 (2.7)</td>
<td>16.1</td>
</tr>
<tr>
<td>apoE (mg/dl)</td>
<td>4.52 (0.89)</td>
<td>6.03 (1.86)</td>
<td>4.94 (1.12)</td>
<td>6.4</td>
</tr>
</tbody>
</table>
are consistent with a model in which the P376L sequence variant alters the endogenous posttranslational N-glycosylation of SR-BI to prevent either transit from the ER to the Golgi or further posttranslational modifications in the Golgi, which ultimately result in reduced cell surface expression.

**SCARB1 P376L is associated with increased risk of CHD in humans**

Despite a profound increase in HDL-C, SR-BI deficiency in mice causes accelerated atherosclerosis (17–20). The relationship of reduced SR-BI function to atherosclerotic cardiovascular disease in humans has not been established. The P376L homozygous subject did not have clinical CHD, but her carotid intimal-medial thickness (cIMT) was 0.789 mm (left-right average), which is in the >75th percentile for females of her age; in addition, she had detectable plaque throughout the left internal carotid artery and at the bifurcation of her right internal carotid artery. cIMT measurements were not significantly different in the P376L heterozygotes compared with both groups of controls (fig. S8), but because of small sample size, the statistical power is limited.

To achieve greater statistical power to address this question, we performed a meta-analysis of large exome array genotyping studies of CHD cases and healthy controls to determine the relationship of the P376L variant with risk of CHD (Table 3). Among 16 sample sets from two consortia [the CARDIoGRAM Exome Consortium and the CHD Exome+ Consortium], we tested the association between P376L carrier status and CHD in 137,995 individuals. Across 49,846 CHD cases and 88,149 CHD controls, we found that P376L carriers had a significantly higher risk of CHD compared with noncarriers [odds ratio for disease among carriers = 1.79; \( P = 0.018 \)] (Table 3). Thus, carriers of this SCARB1 P376L variant have significantly increased HDL-C levels and a significantly increased risk of CHD.

**Discussion**

Studies of mice have provided important insights into the effects of SR-BI on HDL metabolism, RCT, and atherosclerosis. These studies revealed that overexpression of SR-BI reduces HDL-C (7–10) and reduces atherosclerosis (14–16), whereas gene deletion of SR-BI increases HDL-C (11–13) and accelerates atherosclerosis (17–20). The clinical relevance of these findings has remained uncertain, however. Studies of injected labeled HDL-CE in humans suggested that the majority of the HDL-CE was transported to the liver via
CETP-mediated exchange to apoB-containing lipoproteins rather than by direct uptake from HDL by the liver (30), which brings into question the importance of hepatic SR-BI in human physiology. Common genetic variants near the SCARB1 locus were found to be significantly associated with plasma HDL-C levels, which suggests that SR-BI may play a role in HDL metabolism in humans (22, 31). A family with a rare SCARB1 variant in which serine replaces proline 297 (P297S) was reported in which the heterozygous carriers of the variant had modestly elevated HDL-C levels (31). However, the variant retains substantial SR-BI activity, no homozygotes were identified, the apparent effect on HDL-C was modest, and there was insufficient power to address its effects on atherosclerosis.

Through sequencing of subjects with extremely high plasma levels of HDL-C, we identified a homozygote for a P376L variant in SR-BI. Our complementary approaches consistently demonstrated that this variant confers virtually complete loss of function of SR-BI. Our results demonstrate many similarities in the consequences of SR-BI deficiency on HDL composition between mice and humans, including a shift toward large, buoyant HDL particles and a significant increase in apoA-I, but not apoA-II, in plasma and HDL (22, 32, 33). The homozygote is a woman who had two healthy children without fertility issues or delivery complications, which suggests that, in humans, SR-BI deficiency may not impair reproductive function in the same manner as it does in mice (18, 34). In mice, SR-BI-mediated CE uptake from HDL is a critical process underlying steroid hormone synthesis in adrenal and gonadal tissues, and SR-BI deficiency alters adrenal cholesterol content, impairs adrenal glucocorticoid response under stress, and can lead to fasting-induced hypoglycemia (6, 35, 36). We did not observe any differences in fasting glucose, serum cortisol, adrenocorticotropic hormone, or female gonadal hormones in P376L heterozygous subjects versus controls, and we saw only a modest increase in testosterone in male P376L heterozygotes relative to noncarriers. We postulate that differences in expression or capacity for up-regulation of apoB-containing lipoprotein receptors relative to SR-BI between mouse models and humans in steroidogenic tissues may account, at least partially, for the lack of recapitulation of some of the phenotypes of SR-BI deficiency in mice. We also observed no differences in platelet levels, cholesterol content, and activation from the P376L carriers, despite reports of thrombocytopenia and altered platelet activity in Scarb1 KO mice (37). These results suggest a relatively different contribution of SR-BI to platelet function between mice and humans. Note that the phenotypes of human SCARB1 P376L homozygote (elevated HDL-C and large HDL particles but relatively normal steroidogenesis, reproductive viability, and platelet function) are comparable to those observed in mice lacking PDZ domain containing 1 (PDZK1), an adaptor protein for SR-BI (37).

Perhaps the most important finding of our study is that, despite the elevation in HDL-C, P376L carriers exhibit increased risk of CHD, as do Scarb1 KO mice. Our results are consistent with a growing theme in HDL biology that steady-state concentrations of HDL-C are not causally protective against CHD and that HDL function and cholesterol flux may be more important than absolute levels. Using an in vivo assay of macrophage RCT, we previously showed that Scarb1 KO mice have impaired macrophage RCT even though they have elevated HDL-C levels (21). Our results suggest that reduced hepatic SR-BI function in humans causes impaired RCT, which leads to increased risk of CHD despite elevation in HDL-C levels. However, SR-BI is also expressed in vascular cell types, including endothelial cells, vascular smooth muscle cells, and macrophages, where it could have protective effects against atherosclerosis as well (38, 39). Our results are also consistent with the previously suggested concept (39) that up-regulation or enhancement of SR-BI...
could be a novel therapeutic approach to reducing CHD risk in the general population.

REFERENCES AND NOTES


ACKNOWLEDGMENTS

We appreciate the participation and support of participants of the deep clinical phenotyping studies. We thank E. Mohler for assistance in the interpretation of cMRI results and E. Pashos for helpful discussions. We also acknowledge J. Tabitha-Martinez for expert assistance with clinical phenotyping studies. This work was supported in part by a grant from the National Center for Research Resources (grant TLR002413) and National Center for Advancing Translational Sciences of the NIH (grant TLR000338) to support patient recruitment. D.B.L. was supported by a fellowship from the Dorn Duke Charitable Foundation. S.K. has financial relationships with Novartis, Aegerion, Bristol-Myers Squibb, Sanofi, AstraZeneca, Amryln, Eli Lilly, Leekin Partners, Merck, Catabasis, Regeneron Genetic Center, San Therapeutics, and Cetera. H.S. has financial relationships with MSD Sharp and Dodge, Sanofi-Aventis, and Aegerion. S.B. has financial relationships with Boehringer Ingelheim, Bayer, Novartis, Roche, and Thermo Fisher. N.S. has financial relationships with Amgen, Sanofi, AstraZeneca, and MSD Sharp and Dodge. A.K. has a financial relationship with Aegerion; J.D. has a financial relationship with Novartis. A.T.-H. has financial relationships with Eli Lilly and LGZ Genomics. Sequencing data have been deposited in GenBank (SR0458006).

Genotyping data have been deposited in the Gene Expression Omnibus (GSE76005).

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/351/6278/1166/suppl/DC1

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/351/6278/1166/suppl/DC1

CHEMICAL PHYSICS

Wavelike charge density fluctuations and van der Waals interactions at the nanoscale

Alberto Ambrosetti,1,2 Nicola Ferri,1 Robert A. DiStasio Jr.,3* Alexandre Tkatchenko1,4*

Recent experiments on noncovalent interactions at the nanoscale have challenged the basic assumptions of commonly used particle- and fragment-based models for describing van der Waals (vdW) or dispersion forces. We demonstrate that a qualitatively correct description of the vdW interactions between polarizable nanostructures over a wide range of finite distances can only be attained by accounting for the wavelike nature of charge density fluctuations. By considering a diverse set of materials and biological systems with markedly different dimensionalities, topologies, and polarizabilities, we find a visible enhancement in the nonlocality of the charge density response in the range of 10 to 20 nanometers. These collective wavelike fluctuations are responsible for the emergence of nontrivial modifications of the power laws that govern noncovalent interactions at the nanoscale.

The assembly of complex nanostructures and biological systems from simpler building blocks is often driven by noncovalent van der Waals (vdW) or dispersion interactions that arise from electrodynamic correlations between instantaneous charge fluctuations in matter (1, 2). The influence of vdW forces extends well beyond binding energies and encompasses the structural (3, 4), mechanical (5, 6), spectroscopic (7), and even electronic (8) signatures of condensed matter. A common way to characterize vdW interactions is by power laws in the distance D between two or more objects (e.g., atoms, molecules, nanostructures, surfaces, or solids); the most familiar is arguably the Lennard-Jones potential, which is characterized by a short-range repulsive wall with a D−12 dependence and a long-range attractive tail with a D−6 dependence. Even a slight variation in this power laws can have a profound impact on observed properties and therefore demands an accurate, physically sound theoretical description.

Thus far, both our conceptual understanding of vdW interactions and the quantitative models widely used for describing such quantum mechanical phenomena are primarily rooted in low-order intermolecular perturbation theory (IPT), wherein vdW binding originates from the interactions between transient local multipoles (9), and macroscopic Lifshitz theory (10). Although IPT-based approaches have had enormous success in describing vdW binding in (small) gas-phase molecular systems (11, 12), recent advanced experimental techniques have produced several findings that are challenging the basic assumptions of IPT and macroscopic approaches for nanostructured materials, and are strongly indicative that even our qualitative understanding of these interactions is incomplete and needs to be substantially revised (13). Examples of such experimental observations include (i) ultra-long-range vdW interactions extending up to tens of nanometers into heterogeneous dielectric interfaces (14, 15), (ii) complete screening of the vdW interaction between an atomic force microscope (AFM) tip and a SiO2 surface by the presence of one or more layers of graphene adsorbed on the surface (16), (iii) super-long linear power laws for the self-assembly of metallic clusters on carbon nanotubes with increasing surface area (17), and (iv) nonlinear increases in the vdW attraction between homologous molecules and an Au(111) surface as a function of molecular size (18). Satisfactory theoretical explanations for these experimental findings either require ad hoc modifications to IPT [(iii) and (iv)] or are inherently outside the domain of applicability of IPT [(i) and (ii)].

To address these issues, we note that the spatial extent of the instantaneous charge density fluctuations responsible for vdW interactions depends rather sensitively on the nature and character of the occupied-to-virtual transitions of the
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease
Paolo Zanoni et al.
Science 351, 1166 (2016);
DOI: 10.1126/science.aad3517

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by clicking here.

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines here.

The following resources related to this article are available online at www.sciencemag.org (this information is current as of March 14, 2016):

Updated information and services, including high-resolution figures, can be found in the online version of this article at:
/content/351/6278/1166.full.html

Supporting Online Material can be found at:
/content/suppl/2016/03/09/351.6278.1166.DC1.html

A list of selected additional articles on the Science Web sites related to this article can be found at:
/content/351/6278/1166.full.html#related

This article cites 74 articles, 35 of which can be accessed free:
/content/351/6278/1166.full.html#ref-list-1

This article appears in the following subject collections:
Medicine, Diseases
/cgi/collection/medicine